跳至主要内容
临床试验/NCT05754060
NCT05754060尚未招募不适用

Cognitive Processing Slowness as a Marker of Cognitive Impairment in Non-central Nervous System Cancer Patients

Assistance Publique - Hôpitaux de Paris0 个研究点目标入组 200 人开始时间: 2023年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
200
主要终点
Proportion of patients for which there is a variation of reaction time between the beginning and during the oncological treatment at M4

研究概览

简要总结

Cancer is a frequent disease considering that one person out of three will be confronted with it in their lifetime. Cancer patients often express complaints related to cognitive impairment as an outcome of their oncological treatment. These cognitive disorders have a significant impact on the patient's and their carer's quality of life. Therefore, it appears necessary to have a reliable, quick and simple tool in order to detect cognitive impairment.

The rationale of this study relies on 3 main points :

  • The cognitive complaint frequently reported by cancer patients
  • The difficulty in reliably demonstrating the cause of this complaint through conventional neuropsychological tests
  • The interest of cognitive processing speed as an indicator of cognitive dysfunction

The primary objective of the study is to evaluate a potential variation of cognitive processing speed at the Saint-Louis Lille Battery (SSLIB) between the beginning and during (4 months after the beginning) the oncological treatment of adults with breast cancer or colon cancer.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Beginning an oncological treatment for breast or colon cancer
  • Patients of age ≥ 20 and ≤ 70 years old
  • Cancer diagnosis announcement delivered since less than 3 weeks (+/- a week)
  • Patient affiliated to French social security

排除标准

  • Patient's opposition to the study
  • Notion of an abnormal cerebral scan or MRI
  • Drug use (alcohol, narcotics...)
  • Chronic (≥ 15 days) treatment with corticosteroids > 1mg/kg/j (prednisone or equivalent)
  • Ocular pathology or cognitive disorder impairing comprehension and reading abilities
  • Patients under curatorship, guardianship or under the protection of justice

结局指标

主要结局

Proportion of patients for which there is a variation of reaction time between the beginning and during the oncological treatment at M4

时间窗: At 4 months

The variation will be defined as follows : * Mild if the reaction times vary for only one of the Saint-Louis Lille Battery (SLLIB) tests * Moderate if the variation appears on two of the SLLIB tests * Severe if the variation appears on three of the SLLIB tests

次要结局

  • Anxiety and depression levels(At 12 months)
  • Cognitive complaint(At 12 months)
  • Quality of life assessed with the QLQ-C30 questionnaire(At 12 months)
  • Proportion of patients for which there is a variation of reaction time between the beginning and after the end of the oncological treatment (M12)(At 12 months)
  • Proportion of patients for which there is a variation of reaction time between M4 and M12(At 12 months)

研究者

申办方类型
Other
责任方
Sponsor

相似试验